Indications and uses
temporarily relieves nasal congestion due to: common cold hay fever upper respiratory allergies temporarily relieves sinus congestion and pressure shrinks swollen nasal membranes so you can breathe more freely
temporarily relieves nasal congestion due to: common cold hay fever upper respiratory allergies temporarily relieves sinus congestion and pressure shrinks swollen nasal membranes so you can breathe more freely
adults and children 6 to under 12 years of age (with adult supervision): 2 or 3 sprays in each nostril not more often than every 10 to 12 hours. Do not exceed 2 doses in any 24-hour period. children under 6 years of age: ask a doctor. To spray, squeeze bottle quickly and firmly. Do not tilt head backward while spraying. Wipe nozzle clean after use.
store between 20° to 25°C (68° to 77°F) retain carton for future reference on full labeling
Drug Facts
Oxymetazoline hydrochloride 0.05%
Nasal decongestant
Stop use and ask a doctor if symptoms persist
If pregnant or breast-feeding, ask a health professional before use.
Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away.
To spray, squeeze bottle quickly and firmly. Do not tilt head backward while spraying. Wipe nozzle clean after use.
benzalkonium chloride solution, edetate disodium, polyethylene glycol, povidone, propylene glycol, purified water, sodium phosphate dibasic, sodium phosphate monobasic
Call 1-800-317-2165
Afrin
®
Oxymetazoline HCl Nasal Solution-Nasal Decongestant
Original
NASAL SPRAY
Fast, Powerful
Congestion
Relief
Colds • Allergies
up to 12
Hour
Relief
Maximum
Strength
#1 Doctor & Pharmacist
Recommended Brand
1/2 FL OZ (15 mL)
| RxCUI | RxNorm string | TTY | SPL version |
|---|---|---|---|
| 1000992 | Afrin 0.05 % Nasal Spray | PSN | 12 |
| 1000990 | oxymetazoline HCl 0.05 % Nasal Spray | PSN | 12 |
| 1000992 | oxymetazoline hydrochloride 0.5 MG/ML Nasal Spray [Afrin] | SBD | 12 |
| 1000990 | oxymetazoline hydrochloride 0.5 MG/ML Nasal Spray | SCD | 12 |
| 1000992 | Afrin 0.05 % Nasal Spray | SY | 12 |
| 1000992 | Afrin 0.5 MG/ML Nasal Spray | SY | 12 |
| 1000990 | oxymetazoline hydrochloride 0.05 % Nasal Spray | SY | 12 |
| Class | Version | Type | Effective |
|---|---|---|---|
| OXYMETAZOLINE Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20180813 |
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| e67be450-f8e4-4bc1-88bd-1259d379f55f | Product name | 1 | 20210127 |
| c53f3286-4062-4cf5-8355-399519c639a6 | Product name | 1 | 20170424 |
| a993dfc5-f219-4460-bde6-30dd724d9ef0 | Product name | 1 | 20160818 |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 11523-1167-1 | AfrinOriginal | 6 mL in 1 BOTTLE, SPRAY | SPRAY | 6 | 12 | |
| 11523-1167-2 | AfrinOriginal | 21 mL in 1 BOTTLE, SPRAY | SPRAY | 21 | 12 | |
| 11523-1167-2 | AfrinOriginal | 2 in 1 CARTON | SPRAY | 2 | 12 | |
| 11523-1167-3 | AfrinOriginal | 1 in 1 CARTON | SPRAY | 1 | 12 | |
| 11523-1167-3 | AfrinOriginal | 20 mL in 1 BOTTLE, SPRAY | SPRAY | 20 | 12 | |
| 11523-1167-4 | AfrinOriginal | 3 in 1 CARTON | SPRAY | 3 | 12 | |
| 11523-1167-4 | AfrinOriginal | 30 mL in 1 BOTTLE, SPRAY | SPRAY | 30 | 12 | |
| 11523-1167-5 | AfrinOriginal | 30 mL in 1 BOTTLE, SPRAY | SPRAY | 30 | 12 | |
| 11523-1167-5 | AfrinOriginal | 1 in 1 CARTON | SPRAY | 1 | 12 | |
| 11523-1167-6 | AfrinOriginal | 15 mL in 1 BOTTLE, SPRAY | SPRAY | 15 | 12 | |
| 11523-1167-6 | AfrinOriginal | 1 in 1 CARTON | SPRAY | 1 | 12 |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 11523-1167-3 | ML - Milliliter | 11523-1167 | e6b61680-eaad-4ff1-a0d4-d25116e1ada1 | 1 | 2015-10-02 |
| 11523-1167-5 | ML - Milliliter | 11523-1167 | 892df7b8-5889-48d3-9cdf-70a8f33e8c49 | 1 | 2013-10-17 |
| 11523-1167-6 | ML - Milliliter | 11523-1167 | 5797e12f-28cc-49e5-bfd1-5dc75045522c | 1 | 2013-10-17 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| Oxymetazoline hydrochloride | ACTIVE INGREDIENT | K89MJ0S5VY | 2 | |
| Oxymetazoline | ACTIVE MOIETY | 8VLN5B44ZY | 2 | |
| benzalkonium chloride | INACTIVE INGREDIENT | F5UM2KM3W7 | 2 | |
| edetate disodium | INACTIVE INGREDIENT | 7FLD91C86K | 2 | |
| polyethylene glycols | INACTIVE INGREDIENT | 3WJQ0SDW1A | 2 | |
| povidones | INACTIVE INGREDIENT | FZ989GH94E | 2 | |
| propylene glycol | INACTIVE INGREDIENT | 6DC9Q167V3 | 2 | |
| sodium phosphate, dibasic | INACTIVE INGREDIENT | GR686LBA74 | 2 | |
| sodium phosphate, monobasic | INACTIVE INGREDIENT | 3980JIH2SW | 2 | |
| water | INACTIVE INGREDIENT | 059QF0KO0R | 2 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 11523-1167 | 11523-1167-2, 11523-1167-3, 11523-1167-4, 11523-1167-5, 11523-1167-6, 11523-1167-1 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| SODIUM PHOSPHATE, DIBASIC | GR686LBA74 | IACT |
| SODIUM PHOSPHATE, MONOBASIC | 3980JIH2SW | IACT |
| OXYMETAZOLINE HYDROCHLORIDE | K89MJ0S5VY | ACTIB |
| EDETATE DISODIUM | 7FLD91C86K | IACT |
| BENZALKONIUM CHLORIDE | F5UM2KM3W7 | IACT |
| POLYETHYLENE GLYCOL, UNSPECIFIED | 3WJQ0SDW1A | IACT |
| POVIDONE | FZ989GH94E | IACT |
| PROPYLENE GLYCOL | 6DC9Q167V3 | IACT |
| WATER | 059QF0KO0R | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| sodium phosphate, dibasic | SODIUM PHOSPHATE, DIBASIC | GR686LBA74 | SUSPENSION / OPHTHALMIC | 0.43 %w/w | ||
| sodium phosphate, monobasic | SODIUM PHOSPHATE, MONOBASIC | 3980JIH2SW | INJECTION, SUSPENSION / SUBCUTANEOUS | 0.07 %w/v | ||
| povidones | POVIDONE | FZ989GH94E | TABLET, COATED / ORAL | 49.2 mg | ||
| sodium phosphate, dibasic | SODIUM PHOSPHATE, DIBASIC | GR686LBA74 | FILM, SOLUBLE / ORAL | 9 mg | ||
| sodium phosphate, monobasic | SODIUM PHOSPHATE, MONOBASIC | 3980JIH2SW | INJECTION / INTRAVENOUS | 161 mg | ||
| benzalkonium chloride | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | SPRAY / NASAL | 1 mg | ||
| povidones | POVIDONE | FZ989GH94E | TABLET, COATED / ORAL | 49.2 mg | ||
| povidones | POVIDONE | FZ989GH94E | TABLET / SUBLINGUAL | 6 mg | ||
| sodium phosphate, dibasic | SODIUM PHOSPHATE, DIBASIC | GR686LBA74 | INJECTION / INTRAVENOUS | 200 mg | ||
| sodium phosphate, monobasic | SODIUM PHOSPHATE, MONOBASIC | 3980JIH2SW | SYSTEM / IONTOPHORESIS | 14.2 mg | ||
| povidones | POVIDONE | FZ989GH94E | CAPSULE / ORAL | 300 mg | ||
| edetate disodium | EDETATE DISODIUM | 7FLD91C86K | SPRAY / NASAL | 1 mg | ||
| povidones | POVIDONE | FZ989GH94E | SYSTEM / TOPICAL | 41 mg | ||
| povidones | POVIDONE | FZ989GH94E | GRANULE, FOR SUSPENSION, EXTENDED RELEASE / ORAL | 350 mg | ||
| sodium phosphate, monobasic | SODIUM PHOSPHATE, MONOBASIC | 3980JIH2SW | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 13.2 mg | ||
| propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | SPRAY / NASAL | 5 mg | ||
| povidones | POVIDONE | FZ989GH94E | SUSPENSION/ DROPS / OPHTHALMIC | 0.6 %w/v | ||
| sodium phosphate, dibasic | SODIUM PHOSPHATE, DIBASIC | GR686LBA74 | SOLUTION / ORAL | 40 mg/1ml | ||
| povidones | POVIDONE | FZ989GH94E | SOLUTION / OPHTHALMIC | 1.8 %w/v | ||
| povidones | POVIDONE | FZ989GH94E | SUSPENSION/ DROPS / OPHTHALMIC | 0.6 %w/v | ||
| povidones | POVIDONE | FZ989GH94E | SYSTEM / TOPICAL | 41 mg | ||
| sodium phosphate, dibasic | SODIUM PHOSPHATE, DIBASIC | GR686LBA74 | INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR | 40 mg | ||
| povidones | POVIDONE | FZ989GH94E | TROCHE / ORAL | 30 mg | ||
| sodium phosphate, dibasic | SODIUM PHOSPHATE, DIBASIC | GR686LBA74 | SYRUP / ORAL | 70 mg | ||
| povidones | POVIDONE | FZ989GH94E | SUSPENSION / ORAL | 20 mg/5ml | ||
| povidones | POVIDONE | FZ989GH94E | TABLET / SUBLINGUAL | 6 mg | ||
| povidones | POVIDONE | FZ989GH94E | SYSTEM / TOPICAL | 41 mg | ||
| sodium phosphate, dibasic | SODIUM PHOSPHATE, DIBASIC | GR686LBA74 | CONCENTRATE / ORAL | 17 mg/5ml | ||
| povidones | POVIDONE | FZ989GH94E | FILM, EXTENDED RELEASE / TRANSDERMAL | NA | ||
| povidones | POVIDONE | FZ989GH94E | FILM, EXTENDED RELEASE / TRANSDERMAL | NA | ||
| povidones | POVIDONE | FZ989GH94E | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 17 mg | ||
| sodium phosphate, monobasic | SODIUM PHOSPHATE, MONOBASIC | 3980JIH2SW | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / SUBCUTANEOUS | 0.22 mg | ||
| povidones | POVIDONE | FZ989GH94E | TABLET, FOR SUSPENSION / ORAL | 2 mg | ||
| povidones | POVIDONE | FZ989GH94E | SYSTEM / TOPICAL | 41 mg | ||
| povidones | POVIDONE | FZ989GH94E | TABLET, FOR SUSPENSION / ORAL | 2 mg | ||
| povidones | POVIDONE | FZ989GH94E | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 17 mg | ||
| sodium phosphate, dibasic | SODIUM PHOSPHATE, DIBASIC | GR686LBA74 | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 40 mg | ||
| povidones | POVIDONE | FZ989GH94E | CAPSULE, DELAYED RELEASE / ORAL | NA | ||
| sodium phosphate, dibasic | SODIUM PHOSPHATE, DIBASIC | GR686LBA74 | FILM, SOLUBLE / ORAL | 9 mg | ||
| povidones | POVIDONE | FZ989GH94E | TABLET, ORALLY DISINTEGRATING / ORAL | 15.03 mg | ||
| sodium phosphate, dibasic | SODIUM PHOSPHATE, DIBASIC | GR686LBA74 | INJECTION / SUBCUTANEOUS | 14 mg | ||
| edetate disodium | EDETATE DISODIUM | 7FLD91C86K | SPRAY / NASAL | 1 mg | ||
| povidones | POVIDONE | FZ989GH94E | TABLET, COATED / ORAL | 49.2 mg | ||
| sodium phosphate, monobasic | SODIUM PHOSPHATE, MONOBASIC | 3980JIH2SW | INJECTION, SUSPENSION / SUBCUTANEOUS | 0.07 %w/v | ||
| povidones | POVIDONE | FZ989GH94E | TROCHE / ORAL | 30 mg | ||
| sodium phosphate, dibasic | SODIUM PHOSPHATE, DIBASIC | GR686LBA74 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / SUBCUTANEOUS | 2.98 mg | ||
| povidones | POVIDONE | FZ989GH94E | POWDER, FOR SUSPENSION / ORAL | 35 mg/5ml | ||
| povidones | POVIDONE | FZ989GH94E | GRANULE, FOR SUSPENSION, EXTENDED RELEASE / ORAL | 350 mg | ||
| sodium phosphate, dibasic | SODIUM PHOSPHATE, DIBASIC | GR686LBA74 | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 40 mg | ||
| povidones | POVIDONE | FZ989GH94E | TABLET, DELAYED RELEASE / ORAL | 53 mg | ||
| sodium phosphate, dibasic | SODIUM PHOSPHATE, DIBASIC | GR686LBA74 | SYRUP / ORAL | 70 mg | ||
| povidones | POVIDONE | FZ989GH94E | TABLET / ORAL | 216 mg | ||
| sodium phosphate, monobasic | SODIUM PHOSPHATE, MONOBASIC | 3980JIH2SW | SYSTEM / IONTOPHORESIS | 14.2 mg | ||
| benzalkonium chloride | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | SPRAY / NASAL | 1 mg | ||
| sodium phosphate, dibasic | SODIUM PHOSPHATE, DIBASIC | GR686LBA74 | TABLET, EXTENDED RELEASE / ORAL | 143 mg | ||
| sodium phosphate, monobasic | SODIUM PHOSPHATE, MONOBASIC | 3980JIH2SW | SYSTEM / IONTOPHORESIS | 14.2 mg | ||
| povidones | POVIDONE | FZ989GH94E | SUSPENSION / OPHTHALMIC | 1.8 %w/v | ||
| povidones | POVIDONE | FZ989GH94E | CAPSULE, EXTENDED RELEASE / ORAL | 56 mg | ||
| povidones | POVIDONE | FZ989GH94E | IMPLANT / SUBCUTANEOUS | 6 mg | ||
| povidones | POVIDONE | FZ989GH94E | CAPSULE, EXTENDED RELEASE / ORAL | 56 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Afrin Original | OXYMETAZOLINE HYDROCHLORIDE | Bayer HealthCare LLC. | 89c165ba-3ad5-49b5-a5bb-423dc8e15bad | 2025-12-04 | Warnings | 11523-1167-2 11523-1167-1 11523-1167-4 11523-1167-3 11523-1167-5 11523-1167-6 11523-1167 11523116705 11523116702 11523116703 11523116701 11523116706 11523116704 452362c1-c953-c5d7-e063-6294a90ad7c4 89c165ba-3ad5-49b5-a5bb-423dc8e15bad |
Adverse event summaries are temporarily unavailable. Other product information remains available.